PaxMedica CEO Interviewed by The BRAIN Foundation
Webcast Link Available at PaxMedica.com TARRYTOWN, NY, June 20, 2023 (GLOBE NEWSWIRE) — via NewMediaWire…
News
PaxMedica CEO Interviewed by The BRAIN Foundation
Webcast Link Available at PaxMedica.com TARRYTOWN, NY, June 20, 2023 (GLOBE NEWSWIRE) — via NewMediaWire…
BioSyent Announces Long-term Extension of Cathejell® Agreement
MISSISSAUGA, Ontario, June 20, 2023 (GLOBE NEWSWIRE) — BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture:…
BioSyent Announces Long-term Extension of Cathejell® Agreement
MISSISSAUGA, Ontario, June 20, 2023 (GLOBE NEWSWIRE) — BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture:…
Intelligent Bio Solutions Receives Non-Dilutive Grant Funding of USD $1.43 Million
Grant Funding received to date from the Australian Federal Government totals USD $3.25 million NEW…
Intelligent Bio Solutions Receives Non-Dilutive Grant Funding of USD $1.43 Million
Grant Funding received to date from the Australian Federal Government totals USD $3.25 million NEW…
ABVC BioPharma Subsidiary BioKey Projects $1.0 Million Proceeds From Dietary Supplement Production
FREMONT, CA, June 20, 2023 (GLOBE NEWSWIRE) — via NewMediaWire — ABVC BioPharma, Inc. (NASDAQ:…
ABVC BioPharma Subsidiary BioKey Projects $1.0 Million Proceeds From Dietary Supplement Production
FREMONT, CA, June 20, 2023 (GLOBE NEWSWIRE) — via NewMediaWire — ABVC BioPharma, Inc. (NASDAQ:…
Sequantrix Launches Operations
Sequantrix identifies and validates novel, antifibrotic targets by leveraging one of the world’s largest human…
Sequantrix Launches Operations
Sequantrix identifies and validates novel, antifibrotic targets by leveraging one of the world’s largest human…
Harvard Bioscience Appoints Jennifer Cote as Chief Financial Officer
Has served in interim role since January 2023 HOLLISTON, Mass., June 20, 2023 (GLOBE NEWSWIRE)…
Harvard Bioscience Appoints Jennifer Cote as Chief Financial Officer
Has served in interim role since January 2023 HOLLISTON, Mass., June 20, 2023 (GLOBE NEWSWIRE)…
HMNC Brain Health Begins Phase 2 Study for Personalized Treatment of Stress-Axis Related Major Depressive Disorder (MDD)
The Company’s Nelivabon Program Pairs Novel Compound with Companion Diagnostics to Treat MDD patients MUNICH,…
HMNC Brain Health Begins Phase 2 Study for Personalized Treatment of Stress-Axis Related Major Depressive Disorder (MDD)
The Company’s Nelivabon Program Pairs Novel Compound with Companion Diagnostics to Treat MDD patients MUNICH,…
Grace Breeding Announces Brazil Field Test Results of its ProMagen™ (WDS Bio-Activator) in Soybean Plants Demonstrating Boosted Yields
– Using ProMagen™ in combination with standard chemicals or other biological solutions demonstrated more efficient…
Grace Breeding Announces Brazil Field Test Results of its ProMagen™ (WDS Bio-Activator) in Soybean Plants Demonstrating Boosted Yields
– Using ProMagen™ in combination with standard chemicals or other biological solutions demonstrated more efficient…
Appeal of Delisting Determination
20 June 2023 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Appeal of Delisting Determination Biodexa Pharmaceuticals…
Appeal of Delisting Determination
20 June 2023 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Appeal of Delisting Determination Biodexa Pharmaceuticals…
PDS Biotech to be Added to Russell 2000® and Russell 3000® Indexes Effective June 26, 2023
FLORHAM PARK, N.J., June 20, 2023 (GLOBE NEWSWIRE) — PDS Biotechnology Corp. (NASDAQ: PDSB), a…
PDS Biotech to be Added to Russell 2000® and Russell 3000® Indexes Effective June 26, 2023
FLORHAM PARK, N.J., June 20, 2023 (GLOBE NEWSWIRE) — PDS Biotechnology Corp. (NASDAQ: PDSB), a…